Inactive Instrument

Cubist Pharmaceuticals Inc Share Price

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/14/10	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/14/09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/14/10	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/14/09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/14/09	Merck : to take on superbugs with Cubist Pharma buy	RE
09/14/09	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/14/09	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/14/08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/14/06	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/13/21	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/15/13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/14/20	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
09/14/09	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
09/14/09	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
08/14/08	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU

21/14/21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
21/14/21	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/14/09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/14/08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/14/08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	-1.48%	-7.35%	+40.60%	-5.92%	7.92TCr
CSL LIMITED	-1.42%	-4.79%	-20.78%	-38.31%	5.82TCr
MODERNA, INC.	+5.38%	-3.29%	+492.23%	+33.75%	5.45TCr
SAMSUNG BIOLOGICS CO.,LTD.	-0.56%	-4.20%	-11.00%	+27.11%	4.89TCr
UCB	+1.93%	-6.84%	-1.34%	+149.15%	4.47TCr
BIOGEN INC.	+0.80%	-3.28%	+52.27%	-16.16%	3.18TCr
INCYTE CORPORATION	-1.47%	-5.10%	+40.83%	+89.86%	2.5TCr
INNOVENT BIOLOGICS, INC.	-0.85%	-8.82%	-6.07%	+164.64%	2.09TCr
SWEDISH ORPHAN BIOVITRUM AB	-0.09%	-4.70%	+62.73%	+102.03%	1.58TCr
Average	-0.31%	-5.31%	+72.16%	+56.24%	4.21TCr
Weighted average by Cap.	-0.40%	-5.38%	+83.88%	+36.74%